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Abstract 34 
Common in vitro toxicity testing often neglects the fate and intracellular concentration of tested 35 
compounds, potentially limiting the predictability of in vitro results for in vivo extrapolation. We used in 36 
vitro long-term cultures of primary rat (PRH) and human hepatocytes (PHH) and HepaRG cells to 37 
characterise and model the biokinetic profile of ibuprofen (IBU) after single and daily repeated 38 
exposure (14 days) to two concentrations. A cross-model comparison was carried out at 100 µM, 39 
roughly corresponding to the human therapeutic plasma concentration. Our results showed that IBU 40 
uptake was rapid and a dynamic equilibrium was reached within 1 or 2 days. All three cell systems 41 
efficiently metabolised IBU. In terms of species-differences, our data mirrored known in vivo results. 42 
Although no bioaccumulation was observed, IBU intracellular concentration was higher in PRH due to 43 
a 10-fold lower metabolic clearance compared to the human-derived cells. In HepaRG cells, IBU 44 
metabolism increased over time, but was not related to the treatment. In PHH, a low CYP2C9 activity, 45 
the major IBU-metabolising CYP, led to an increased cytotoxicity. A high inter-individual variability was 46 
seen in PHH, whereas HepaRG cells and PRH were more reproducible models. Although the 47 
concentrations of IBU in PRH over time differed from the concentrations found in human cells under 48 
similar exposure conditions. 49 
 50 
Keywords: Biokinetics, Ibuprofen, in vitro, Primary rat hepatocytes, Primary human hepatocytes, 51 
HepaRG cells 52 
53 
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Abbreviations 54 
ADR - adverse drug reaction 55 
bcell - biliary cell 56 
BSA - bovine serum albumin 57 
Ccell - concentration in cell lysate 58 
Cmax - human therapeutic peak plasma concentration 59 
Cmed - concentration in assay medium 60 
CV- coefficient of variation 61 
CYP - cytochrome P450 62 
DME - drug metabolising enzyme 63 
DMEM - Dulbecco modified eagle medium 64 
DMSO - dimethyl sulphoxide 65 
FBS - foetal bovine serum 66 
Fin - entry rate flow for one cell 67 
Fout - exit rate flow for one cell 68 
HMM - hepatocyte maintenance medium 69 
IBU - ibuprofen 70 
ITS - insulin transferrin selenium 71 
k1 - rate constant for binding to medium proteins 72 
k2 - rate constant for unbinding from medium proteins 73 
Km - Michaelis-Menten constant 74 
LOD- Limit of detection 75 
LOQ – Limit of quantification 76 
MCMC - Markov-chain Monte Carlo 77 
Ncell - number of cells in the assay system 78 
NOAEC – No observed adverse effect concentration 79 
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OECD - Organisation for Economic Co-operation and Development 80 
PHH - primary human hepatocytes 81 
PBPK - physiologically-based pharmacokinetics 82 
PRH - primary rat hepatocytes 83 
Qcell - total quantity in cell lysate 84 
Qmed - total quantity in assay medium 85 
Qprot - total quantity bound on protein 86 
SD - standard deviation 87 
SW - sandwich 88 
t1/2 - half-life 89 
TC - toxic concentration 90 
Tmax - time to reach Cmax 91 
Vcell - volume of cells 92 
Vmax - maximal metabolic rate 93 
Vmed - volume of assay medium 94 
95 
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1 Introduction 96 
Attrition during drug discovery and development is a major hurdle to the launch of a drug and lack of 97 
efficacy and unacceptable toxicity are the two major reasons (Kola and Landis, 2004). Usually, the 98 
potential risk for human health of pharmaceuticals is assessed in the early phases of development on 99 
the basis of animal testing. However, the extrapolation of observed adverse drug reactions (ADRs) 100 
from animals to humans is often difficult. The discrepancies can be frequently attributed to different 101 
kinetic behaviours of the compound in the different species (Shanks et al., 2009). 102 
In the last decades, in vitro models have improved substantially, resulting in applications accepted as 103 
valuable tools to characterise and optimise compounds in terms of efficacy and safety. Most of these 104 
in vitro models apply a single exposure to deliver discrete information on single endpoints. By contrast, 105 
more complex in vitro models, for the identification of systemic effects, lack acceptance mainly 106 
because they poorly correlate with in vivo data (Adler et al., 2011). Differences between in vitro and in 107 
vivo kinetics have been considered as one of the main reasons. Despite this, the implementation of 108 
biokinetic information in in vitro systems has been mainly ignored. As a consequence, an observed 109 
effect indicated by e.g. EC50 (Effective Concentration causing the 50% of the effect) or NOAEC (No 110 
Observed Adverse Effect Concentration) in vitro is typically assigned to the applied nominal 111 
concentration of the test item, assuming that 100% is available within the cell. On the contrary, a 112 
number of abiotic processes affects the fraction of a test chemical that is available for uptake into cells 113 
or tissue, reducing its bioavailability. These processes include compound solubility, volatility, stability 114 
in aqueous solutions, binding to membrane lipids and proteins in cell culture medium or adsorption to 115 
plastic devices. Furthermore, biotic processes, such as mechanisms of cell uptake/extrusion, 116 
metabolism, intracellular bioaccumulation (of parent and/or metabolites) as well as saturation of these 117 
processes can influence the compound’s biokinetic behaviour, affecting the biologically effective dose 118 
of test chemical, able to interact with the target or cause toxicity. This hampers the interpretation of in 119 
vitro data to predict in vivo dose–response relationships and compare the true toxic potency of test 120 
compounds (Groothuis et al, 2013). Thus, the intracellular concentration is a much more relevant 121 
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parameter to enable the derivation of a NOAEC in vitro. This NOAEC can be then transformed to in 122 
vivo doses using appropriate modelling techniques, such as physiologically-based pharmacokinetics 123 
(PBPK) modelling.  124 
Previous groups have shown that adsorption to plastic devices (Tirelli et al., 2007), binding to 125 
macromolecules in the medium (Guelden et al., 2001; Seibert et al., 2002), evaporation of the 126 
chemical (Kramer et al. 2012) and the number of cells in the cell system (Guelden et al., 2001; 127 
Guelden et al., 2010) influence the actual biologically effective concentration and thus the cytotoxic 128 
potential of a compound. A recent paper reviewed a number of factors affecting bioavailability of test 129 
chemicals in in vitro assays and different dose metrics for in vitro setups (Groothuis et al, 2013).  130 
To further support this concept, the application of a recently developed model to a set of hypothetical 131 
chemicals as well as to 1194 real substances (predominantly from the ToxCast chemical database) 132 
shows that the potential range of concentrations and chemical activities under assumed test 133 
conditions can vary by orders of magnitude for the same nominal concentration (Armitage et al. 2014). 134 
There is an urgent need for predictive in vitro models to identify ADRs in the early phases of drug 135 
development, especially for the liver. As the main drug metabolising organ, the liver plays a central 136 
role in drug-induced toxicities. Furthermore, repeated drug administration is a more relevant exposure 137 
scenario for therapeutics, being usually evaluated in specified in vivo repeated-dose toxicity testing. In 138 
order to mimic repeated exposures in vitro, models retaining in vivo characteristics for a sufficiently 139 
long time frame should be used. Both hepatotoxicity and repeated exposure were addressed in this 140 
work by using different long-term hepatic culture systems. 141 
Primary hepatocytes are the gold standard for metabolism studies because these cells retain in vivo-142 
like activities of drug metabolising enzymes (DMEs) (Guillouzo, 1998; Hewitt et al., 2007; Tuschl et al., 143 
2008). However, monolayer cultures of primary hepatocytes lose the activity of some liver-specific 144 
enzymes within a few days (Guillouzo, 1998; Tuschl et al., 2009). By contrast, primary rat and human 145 
hepatocytes (PRH and PHH, respectively) cultured in a sandwich (SW) configuration with defined 146 
medium, maintain their metabolic capacities at acceptable levels over a prolonged time period 147 
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(Parmentier et al., 2013; Tuschl et al., 2009). The cholangio-hepatocarcinoma derived cell line 148 
HepaRG™ has proven itself valuable for many applications, including the prediction of metabolism-149 
dependent hepatotoxicity (Aninat et al., 2006; Anthérieu et al., 2012). This human-derived cell line is a 150 
promising system, because after proliferation and differentiation phases it holds adequate and rather 151 
stable activity of DMEs throughout long-term culture. 152 
The EU FP7 Project Predict-IV aimed to provide an improved predictability of the non-clinical safety 153 
testing by using in vitro tests, proposed to integrate dynamics and biokinetics in in vitro models after 154 
repeated exposure. This paper describes some of the obtained results comparing the three hepatic 155 
models described above to study the kinetic behaviour of ibuprofen (IBU), after acute and long-term 156 
repeated treatment. 157 
IBU, a non-steroidal anti-inflammatory drug, seldom inducing ADRs in the liver, has been used as 158 
model compound, selected on the basis of its physicochemical and metabolic properties. 159 
To the best of our knowledge the in vitro biokinetics after single (d0/1) and repeated exposures 160 
(d13/14) of a drug are here described for the first time. The integration of biokinetics to well-161 
established rat and human long-term liver culture systems addresses most of the current issues of in 162 
vitro systems described above. The approach further includes the application of PK modelling, by 163 
integrating the kinetic experimental parameters obtained in the different in vitro systems, and being a 164 
fundamental tool for the extrapolation of in vitro data to the in vivo situation. 165 
166 
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2 Materials and Methods 167 
2.1 Chemicals and Reagents 168 
IBU was purchased from Sigma-Aldrich (Steinheim, Germany; St. Quentin-Fallavier, France) or 169 
Calbiochem (Darmstadt, Germany). For the culture of the PRH in sandwich configuration Collagen 170 
from rat tail tendon (Roche, Mannheim, Germany) was used, while PHH were covered with Geltrex™ 171 
from Gibco® (Thermo Fisher Scientific, Illkirch, France). The perfusion buffer components were from 172 
Merck Chemicals (Merck KGaA) and AppliChem (both Darmstadt, Germany) or Sigma-Aldrich 173 
(Steinheim, Germany; St. Quentin-Fallavier, France). DMEM/F12 GlutaMAX™, Williams’ E medium, 174 
Sodium-pyruvate, ITS-G (100x), Gentamycin, Glutamine, Trypsin/EDTA and PBS were obtained from 175 
Gibco® (LifeTechnologies, Darmstadt, Germany; Thermo Fisher Scientific, Illkirch, France). The 176 
culture medium, HMM, used with PHH was purchased from Lonza (Verviers, Belgium). Foetal bovine 177 
serum (FBS) was from HyClone®, Gibco® or Perbio (Thermo Fisher Scientific, Waltham (MA), USA or 178 
Illkirch, France); hydrocortisone hemisuccinate was from Upjohn Pharmacia (Guyancourt, France). 179 
Further reagents were from Sigma-Aldrich (Steinheim, Germany; St. Quentin-Fallavier, France) 180 
included penicillin/streptomycin, insulin, BSA, dexamethasone, percoll® and DMSO. 181 
For IBU quantification analytical grade chemicals were obtained from commercially available sources. 182 
The Milli-Q water purification system (Millipore, Merck KGaA, Darmstadt, Germany) was used to 183 
obtain deionised water. 184 
2.2 Cell culture 185 
2.2.1 Primary rat hepatocytes 186 
Care and use of laboratory animals was in agreement with the German guidelines and approved by 187 
the ethics committee. Isolation of rat hepatocytes from male Wistar rats (Harlan Laboratories, 188 
Rossdorf, Germany) followed a modified two-step perfusion technique described by Seglen (Seglen, 189 
1976). Overall, only hepatocyte preparations with more than 85% viability (determined via trypan 190 
exclusion method) were used. 30,000 viable cells were seeded onto collagen I coated 96-well plates in 191 
serum-containing culture media (DMEM/F12 GlutaMAX™, 100 units/mL penicillin, 100 µg/mL 192 
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streptomycin, 1 mM sodium pyruvate, 10% FBS and 5 µg/mL insulin). Following an attachment phase 193 
of 4 h the culture medium was replaced with serum-free culture medium media (DMEM/F12 194 
GlutaMAX™, 100 units/mL penicillin, 100 µg/mL streptomycin, 1 mM sodium pyruvate, 100 nM 195 
dexamethasone, 0.44 mg/L BSA, ITS-G) and IBU treatment was started 24h after seeding. For the 196 
SW culture format, the cells were seeded in serum-containing culture media on a gelatinised layer of 197 
collagen (prepared at 37°C ≥ 1 h) at a density of 0.25 and 1.5 x 106 viable cells per well in a 24- and 6-198 
well plate (BD Falcon™, Heidelberg, Germany), respectively. After four hours the culture medium was 199 
replaced with fresh serum-containing media. On the subsequent day the top collagen stratum was 200 
applied and after its full gelatinisation (at 37°C ≥ 1.5 h) serum-free culture medium media was added. 201 
IBU treatment started on day 3 after seeding. 202 
2.2.2 Primary Human Hepatocytes 203 
All experiments were performed with permission of the National Ethics Committee (France) and 204 
regulatory authorities. Liver biopsies (20-100 g) were received from surgical operations of patients with 205 
different pathologies (Table 1), whereas the obtained tissue was removed with a safety margin from 206 
the aberrant section. LeCluyse and Alexandre (2010) delineate the two-step perfusion procedure 207 
which was applied to isolate the PHH from the liver resections. 208 
Viability of the PHH suspension, obtained directly after isolation, was assessed via trypan blue 209 
exclusion method and only preparations holding viability greater than 70% were used for cell culture 210 
experiments. The cells were seeded at a density of 2 x 106 viable cells per well of a collagen-coated 6-211 
well BD Biocoat® plate (Dutscher, France) for kinetic studies or at a density of 0.3 x 106 viable cells 212 
per well of a 24-well plate (Biocoat®, Dutscher, France) for CYP450 activity measurements. The 213 
seeding medium was Williams’ E medium containing 50 µg/mL gentamycin, 10% FBS, 1 µM 214 
dexamethasone and 4 µg/mL insulin. Following an overnight incubation the monolayer culture was 215 
covered with a preparation of 350 µg/mL Geltrex™ in serum-free culture media (HMM, 50 µg/mL 216 
gentamycin, 100 nM dexamethasone and 1x ITS-G). The Geltrex™ overlay was renewed every 3-4 217 
days. IBU treatment was started two days after seeding. 218 
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2.2.3 HepaRG cells 219 
The liver tumour derived HepaRG cells were cultured and differentiated as previously described by 220 
Gripon et al. (2002). Briefly, the HepaRG cells (at passage 12) were cultured in growth medium 221 
(Williams’ E supplemented with 10% FBS, 100 units/mL penicillin, 100 µg/mL streptomycin, 5 µg/mL 222 
insulin, 2 mM glutamine, and 50 µM hydrocortisone hemisuccinate), which was refreshed three times 223 
a week. After two weeks the growth medium was supplemented with 2% DMSO for additional two 224 
weeks, resulting in differentiated HepaRG cell cultures. At that time the cultures contained hepatocyte-225 
like and primitive biliary cells at around the same percentage (Cerec et al., 2007; Aninat et al., 2006) 226 
and were ready for treatment with IBU. Two days before treatment start the cells (2x106 per well) were 227 
shifted to a medium containing 2% FBS and 1% DMSO. The percentage of FBS was lowered to 2% to 228 
minimise protein binding of the test item, without altering the cell viability and functionality (data not 229 
shown). 230 
2.3 Determination of CYP450s activity in PHH 231 
Basal CYP450s activities were determined in PHH cultures from the three donors used for kinetic 232 
experiments. After attachment, cell monolayers were washed with warm phosphate buffered saline 233 
(PBS) during 15 min at 37°C, and thereafter incubated at 37°C under air/CO2 (95/5 %) in DMEM with 234 
Glutamax I supplemented with insulin (4 mg/mL), dexamethasone (1 µM) and antibiotics, containing 235 
the substrates as a cocktail: 3 µM midazolam, 100 µM bupropion and 10 µM diclofenac for CYP3A4/5, 236 
CYP2B6 and CYP2C9 respectively, as described by Kanebratt et al. (2008) or with ethoxyresorufin for 237 
CYP1A1/2. At the end of the incubation period, supernatants were collected and stored at -80°C until 238 
analysis. The metabolites midazolam 1’-hydroxylation (CYP3A4/5), diclofenac 4-hydroxylation 239 
(CYP2C9) and bupropion-hydroxylation (CYP2B6) were determined by LC-MS/MS and resorufin by 240 
fluorescence, as described by Alexandre et al. (2012). 241 
2.4 Abiotic processes 242 
2.4.1 Stability and solubility of the test compound 243 
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The stability of IBU in both aqueous solutions and in DMSO (the vehicle used to prepare stock 244 
solutions), was checked in preliminary assays, mimicking the actual experimental conditions. Distilled 245 
water, culture media and IBU solutions in DMSO were kept at 37°C for different incubation times in 246 
glass lab-wear and plastic tubes and analysed by HPLC. 247 
2.4.2 Cross-contamination among wells 248 
In the adjacent wells to those containing IBU at the applied concentrations, a corresponding amount of 249 
DMSO (vehicle control) was added. At the end of the experiment, the content of these control wells 250 
was stored at -80°C until HPLC analysis. The IBU content in these control wells served as an 251 
indication of possible contamination across wells due to IBU evaporation.  252 
2.4.3 Adsorption to plastic devices 253 
In order to measure adsorption to the plastic, once the content of each well was removed, the wells 254 
were washed twice with PBS before adding 2 mL methanol. The plate was sealed with Parafilm, and 255 
kept on a horizontal shaker (350 rpm) at room temperature for 2 h before transferring the complete 256 
volume into a LoBind tube.  257 
2.5 Sequestration by the matrix 258 
To determine the amount of IBU possibly sequestered by proteins in the collagen or Geltrex™ matrix 259 
used for PRH and PHH SW cultures, repeated exposure experiments were conducted with the same 260 
schedule of the main experiment but in the absence of cells (‘blank experiment’). Here, corresponding 261 
volumes of collagen I (PRH) and Geltrex™ (PHH) were exposed to high and low IBU concentrations 262 
or DMSO vehicle control. Sampling was performed on the first (0/1) and last (13/14) day of treatment, 263 
at two time points (2 min and 24 h). 264 
2.6 Assessment of cell viability after IBU exposure 265 
Preliminary experiments were performed to determine the cytotoxicity of IBU. For all applied assays, 266 
the results were expressed as a percentage versus the vehicle treated control. 267 
In PRH, the dose finding was performed in three stages (Table 2), starting with treatment with a broad 268 
concentration range in 96-well plate ML culture for 24 h. After the pre-screen, three biological 269 
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replicates in 24-well plate SW culture were treated for 1, 3 and 14 days to assess a preliminary TC10 270 
(the concentration causing 10% cytotoxicity, in the specific case measured as ATP depletion). Finally, 271 
three concentrations around the determined TC10 were tested in 6-well plate SW cultures, the format 272 
for the final experiments, for 14 days repeated exposure. 273 
The cell viability was determined via ATP levels that were measured using the CellTiter-Glo® 274 
Luminescent Cell Viability Assay (Promega®) according to the manufacturer’s protocol including slight 275 
modifications. Briefly, after the corresponding exposure time cell cultures in 96-, 24- or 6-well plates 276 
were incubated with 100 µL, 600 µL or 900 µL CellTiter-Glo® Reagent for 2 min on an orbital shaker. 277 
After 10 min the luminescence signal was measured. 278 
In PHH, preliminary assessment of IBU cytotoxicity was performed in one culture (donor S0302V, not 279 
further used for kinetic testing): 0.05 x 106 viable cells were seeded onto collagen I coated 96-well 280 
Biocoat® plates (Dutscher, France) in Williams’ E medium supplemented with 10% FBS, 4 µg/mL 281 
insulin, 1 µM dexamethasone and 50 µg/mL gentamycin. Following an overnight incubation, the cell 282 
monolayer was covered with 350 µg/mL Geltrex™ in culture medium without FBS for 24 h. Six IBU 283 
concentrations were tested, corresponding to the concentrations applied to PRH in 24-well SW 284 
cultures (see Table 2). A MTT test was performed after 1, 3 and 14 days of treatment. Here, cells were 285 
incubated with 1 mg/mL thiazolyl blue tetrazolium bromide for 30 min, the supernatant was replaced 286 
by 100 µL DMSO per well. After gentle shaking, the absorbance was measured at 595 nm. 287 
For IBU cytotoxicity determinations, 2.5 x 105 HepaRG cells were seeded per well in 96-well plates as 288 
described previously (Aninat et al., 2006). Briefly, after 1, 3 and 14 days of treatment, medium was 289 
removed and serum-free medium containing MTT (0.5 mg/mL) was added to each well and incubated 290 
for 2 h at 37°C. After removal of the incubation solution, water-insoluble formazan was dissolved in 291 
DMSO and absorbance was measured at 540 nm. 292 
2.7 IBU exposure for kinetic experiments 293 
On the basis of results obtained from the preliminary cytotoxicity tests, the two IBU concentrations 294 
used during the kinetic experiments in the three cell culture systems were set as follows: the TC10 in 295 
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the corresponding hepatic system, to reveal underlying mechanisms of toxicity, without causing a 296 
significant decrease in the number of cells; 1/10 TC10, which should give an insight into 297 
pharmacological actions of the drug on cellular level. Eventually, the applied IBU treatment 298 
concentrations were 10 µM and 100 µM in PRH and HepaRG cells, and 100 µM and 1000 µM in PHH. 299 
Prior to each experiment IBU stock solutions (500- or 1000-fold) were prepared in DMSO and stored 300 
at -20°C until needed. Treatment solutions were prepared by diluting the IBU stocks (50 mM and 5 301 
mM for PRH and 500 mM and 50 mM for PHH) 1:500 in serum-free culture medium, keeping DMSO 302 
concentration at 0.2%. The stock solutions (100 mM and 10 mM) for the HepaRG cells were diluted 303 
(1:1000) in medium containing 1% DMSO and 2% FBS to obtain ready-to-use solutions. Aliquots of 304 
the daily treatment solution (considered as time 0 samples) and of the stock solutions were stored at -305 
80°C until HPLC analysis. 306 
Cell treatment with IBU TC10 and 1/10 TC10 was initiated by adding 1.5 mL (PRH) or 2 mL (PHH and 307 
HepaRG cells) per well of the corresponding ready-to-use solutions or the vehicle (control wells). Per 308 
definition, the day of the first exposure was referred to as day 0 and media were changed on a daily 309 
basis for 14 days. 310 
2.8 Sample preparation for HPLC analysis 311 
A sample of cell culture media at time 0 min (t0) to verify the actual IBU concentration added to the 312 
well, and samples of supernatant and cell lysate were collected on day 0/1 and day 13/14 at 5 different 313 
time points (TP): 2 min, 30 min, 1 h, 3 h and 24 h for PRH and PHH. In parallel, samples to measure 314 
plastic adsorption were prepared on empty wells, as described above. The TP selection was based on 315 
intrinsic characteristics of IBU (e.g. 90-99% protein binding, rapid metabolism with half-life 2-4 hours) 316 
and the cell systems (e.g. metabolic competence). The a priori selected TP were confirmed in a 317 
preliminary experiment for PRH and PHH, whereas for HepaRG cells uptake into the cells was 318 
delayed. Therefore, to get a better description of the kinetic behaviour in HepaRG cells, the initially 319 
selected TP were changed to 30 min, 1 h, 3 h, 6 h and 24 h .  320 
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At the selected TP, the supernatant was pipetted into LoBind tubes, and cells were washed twice with 321 
PBS. The SW cultured PRH and PHH were scraped and transferred into a new LoBind tube; the well 322 
was rinsed with 250 µL methanol, which was added to the same tube. Finally, the cell lysate was 323 
homogenised using an in-probe sonicator and the volume was adjusted with methanol to 1 mL. 324 
HepaRG cells were scraped in 200 µL PBS and transferred into a new LoBind tube containing 600 µL 325 
Methanol. A volume of 200 µL PBS was used to wash the well and after adding it to the same tube, 326 
the cell lysate was homogenised (in-probe sonication). All fractions were stored at -80°C until HPLC 327 
analysis. 328 
2.9 HPLC analysis of IBU 329 
Methanol was selected as the extraction solvent after checking extraction efficiency: IBU recovery 330 
from the 3 media and HepaRG cell lysate was > 95%; for PRH and PHH cell lysate for which the 331 
recovery was ~75% an appropriate correction factor was applied for the calculation of IBU content.  332 
Three times volumes methanol were added to the supernatant collected at t0 and at different TP; the 333 
mixture was vortexed for 30 s. All samples, including cell lysates, were centrifuged (Eppendorf 5417R; 334 
5 min, 4°C, 2500 rpm); the upper phase was transferred into amber glass vials for HPLC analysis. 335 
The HPLC system included a PerkinElmer Series 200 analytical pump, a Restek™ Pinnacle ODS 336 
Amine C18 column, a PerkinElmer LC 235 Diode Array Detector and the PerkinElmer Totalchrom™ 337 
3.1.2 software for data acquisition and evaluation. IBU identification and quantification was based on 338 
the isocratic method described by Hassan et al. (2008) with minor modifications, yielding a better 339 
resolution capacity. The method was specific for IBU and not able to detect its major oxidative 340 
metabolites (OH- and COOH-IBU) and the glucuronides (data not shown). The mobile phase 341 
consisted of a 60:40 (v/v) mixture of methanol and NaH2PO4 (50 mM, pH 6.5), at a flow rate of 0.6 342 
mL/min. The injection volume was 20 µL. The absorption of the eluate was measured continuously at 343 
220 nm (retention time 17 min); the amount of IBU was quantified referring to a calibration straight line 344 
(8 concentrations in triplicate, range 1-250 µM; correlation coefficient R2 = 0.978; LOD = 6.2 nM, LOQ 345 
= 20.6 nM, CV = 4.5%).  346 
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In order to have comparable results across the three biological replicates, the raw data obtained in this 347 
study were normalised against the cell number per well. However, cells/well did not vary significantly 348 
among the different wells, as determined by measuring protein content (in PHH), or detaching 349 
HepaRG cells and counting the number per well (in separate wells close to the ones used for the 350 
kinetic analysis), or by high content imaging in separate plates (in PRH) (data not shown); hence, the 351 
IBU content in different compartments was expressed as nmol per well. 352 
2.10 Pharmacokinetic Modelling 353 
To describe the in vitro pharmacokinetics of IBU, we adapted a three-compartment dynamic model as 354 
previously developed for cyclosporine A (Wilmes et al., 2013). The model describes the change in 355 
time of the total quantity of IBU in the assay medium (Qmed), in cells lysate (Qcell) and bound on 356 
proteins such as collagen, if present, (Qprot) in the assay system (Figure 1). The model is generic for 357 
simple static system and therefore can be applied to different in vitro models as it was shown within 358 
the Predict-IV project with appropriate adjustments. The approach is not dissimilar to the one recently 359 
published by Armitage et al. (2014), which is a steady-state approximation of an in vitro system easy 360 
to compute and suitable for high throughput analyses. Since our goal was to perform a kinetic 361 
analysis, we developed a dynamic model, including more parameters and their calibration, generating 362 
a higher degree of precision in estimates.  363 
No adsorption to plastic vial walls was included, as the obtained experimental data with the three 364 
models showed that none occurred for IBU or that it was negligible. Due to sequestration by collagen, 365 
for PRH the ”multiple binding” processes to medium proteins, collagen walls were modelled as a 366 
single process. For PHH and HepaRG cells there was no evidence of non-specific binding from the 367 
blank experiments, thus it was neglected.. 368 
Since the experimental data showed that IBU can be metabolised within cells, biotransformation was 369 
accounted for in the model. The following three differential equations correspond to the general form 370 
of that model: 371 
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dQmed
dt
= N cell (F outCcell− F inCmed )+ k2Q prot− k1Qmed
 (1) 372 
C med =
Qmed
V med  (2) 373 
C cell =
Qcell
N cellV cell  (3) 374 
where Ncell is the number of cells in the assay system, Ccell and Cmed the concentration of IBU in the 375 
cells and medium respectively, Vcell and Vmed the volumes of a cells and of the medium respectively, Fin 376 
and Fout the entry and exit rate flows for one cell respectively, k1 and k2 the rate constants for binding 377 
and unbinding to medium proteins, respectively. 378 
dQ prot
dt
= k1Qmed− k 2Q prot
 (4) 379 
dQcell
dt
= N cell (F inCmed− F outCcell−
V max⋅Qcell
Km+ Qcell) (5) 380 
where Vmax is maximal rate of metabolism and Km the metabolism Michaelis-Menten constant. In Eq. 5 381 
a cell volume proportionality difference was used in the definition of Km rather than concentrations, 382 
with  no change in the results. The cell volume used for the conversion was 6700 μm3 for 383 
PRH(experimentally determined in-house) and 3400 μm3 for PHH and HepaRG cells (2000). Details of 384 
the parameters used for the modelling are given in Tables S1 and S2 (Supplementary material). 385 
For each model the best fit for exchange rates were used: For PRH, the best fit was obtained using 386 
first order rates for collagen binding and unbinding, cell entry and exit rate and metabolism (the range 387 
of concentration assayed did not include doses high enough to identify a maximum rate of 388 
metabolism). For PRH model Eq. 5 above was therefore replaced by its first order equivalent: 389 
 390 
dQcell
dt
= N cell (F inCmed− F outCcell−
V max
Km
Qcell)
 (5b) 391 
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For PHH, no binding to GelTrex™ was observed and its rate was set to zero, first order cell entry and 392 
exit rate and saturable metabolism gave the best fit. 393 
For HepaRG cells, the model considers that a large number of biliary cells develop are present in the 394 
cell culture. These cells do not metabolise IBU which on the other hand we assumed as able to enter 395 
or exit them, at about the same rate per cell as in hepatocytes. We therefore added an equation to 396 
describe the potential accumulation of IBU in biliary cells (express as Qbcell). In addition, metabolism is 397 
known to increase with time in HepaRG cells (Anthérieu et al., 2010) so we described it as a time-398 
varying first order process. The HepaRG PK model was therefore: 399 
 400 
 401 
 402 
where Nbcell is the number of biliary cells in the assay system and Cbcell the concentration of IBU in 403 
those cells. 404 
To fit the model parameters, statistical distributions of their values were obtained by Bayesian 405 
numerical calibration (Bois, 2009) with the experimental data provided by the experiments described 406 
above. The doses actually measured were used as input to the model, rather than the nominal doses. 407 
As usually done with concentration measurements, the data were assumed to be log-normally 408 
distributed with geometric means given by the corresponding model predictions and geometric 409 
variances sampled from half-normal distributions. Markov-chain Monte Carlo (MCMC) simulations 410 
were performed with GNU MCSim version 5.5.0 (http://www.gnu.org/software/mcsim). Two MCMC 411 
chains were run in parallel for 50,000 iterations. Their convergence was checked on the last 25,000 412 
iterations using the criterion of Gelman and Rubin (1992). In the case of PHH, there were clear 413 
differences between donors, so a hierarchical populations model was used to disentangle variability 414 
from uncertainty in parameter estimation (Gelman et al., 1996; Bauer and Guzy, 2007; Bois et al., 415 
2010). Briefly, each 14-day cell culture was fitted individually, yielding one set of parameters for each. 416 
However, to stabilize inference and pool information between individual cultures, individuals' 417 
dQmed
dt
= N cell (F outCcell− F inCmed )+ N bcell (F outCbcell− F inCmed )+ k 2Q prot− k1Qmed
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parameter values were supposed to vary following predefined non-uniform distributions. We used log 418 
normal distributions. For example, in the case of PHH the cell entry flow rate was supposed to vary log 419 
normally around a "population" mean (unknown, to be estimated together with the individual values) 420 
with an estimated "population" geometric variance. In the end, a set of parameters was obtained for 421 
each individual culture, one set of "population" averages and one set of "population" variances. The 422 
(geometric) population means themselves were specified with the prior distributions given in Table 5. 423 
The (geometric) population variances were assigned half-normal prior distributions. 424 
Numerical integration of the models was performed with GNU MCSim version 5.5.0. Plots were 425 
produced with R, version 2.14.0. 426 
 427 
3 Results 428 
3.1 Abiotic processes 429 
IBU was soluble even at the highest used concentration (i.e. stock solutions), both in the vehicle and 430 
in the culture media, with recovery of known amount of IBU after solubilisation in the range of 97-431 
116%. IBU was chemically stable under the experimental conditions used (i.e. incubation time, 432 
temperature, DMSO and different culture media), with the recovery of known amount of IBU in the 433 
range of 92-115%, in glass labware and 94-110% in plastic tubes. In line with this and IBU’s low 434 
lipophilicity at pH 7.4 (log KOW = 0.8), IBU did not adsorb to the plastic devices used during testing as 435 
shown by no IBU extracted by methanol in the ad hoc assays, and mass balance close to 100% at the 436 
first TP during kinetic experiments (see Figures 2-4, E and F). The media used in the three models 437 
contain a sodium-bicarbonate buffer system, which in a 5% CO2 environment, and maintain an almost 438 
constant pH in the physiological range, not altering IBU ionized state during the 14 days of treatment 439 
and hence also its lipophylicity (log KOW = 2.48-3.30 at pH 5). 440 
No evaporation leading to cross-contamination among wells occurred, in accordance with IBU low 441 
volatility (vapour pressure: 7.08 x 10-3 Pa at 25°C). 442 
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The potentially significant IBU protein binding in the culture media (~99%; Rainsford 2009) was limited 443 
by avoiding the use of serum with PRH (replaced with 0.44 mg/mL BSA) and PHH experiments  and 444 
using 2% FBS (corresponding to 0.8-0.9 mg/mL albumin), in HepaRG cell experiments. This condition 445 
did not alter HepaRG cell viability and performance. and was demonstrated not to affect the uptake of 446 
amiodarone, a drug with protein binding capacity similar to IBU (Pomponio et al, 2014). IBU recovery 447 
(110 ± 10%) from the medium was not influenced by BSA or FBS. 448 
In blank experiments, results showed that collagen I (used with PRH) sequestered IBU in a time- and 449 
concentration-dependent manner (Table 3). IBU levels in collagen increased on d0 up to 15% after 24 450 
h. On d13, the percentages levelled off at around 30% at each time point and concentration, 451 
suggesting a saturation of the extracellular matrix. A fraction of the added concentration (content of t0 452 
media) of 15 and 30%, on d0 and d13, respectively, were factored into the intracellular IBU 453 
concentrations. Amounts <5% of the nominal concentrations were within the experimental variance 454 
and hence were not taken into consideration, also in view of the absence of cells, which are thought to 455 
compete with collagen. 456 
Analyses of Geltrex™ preparations (used with PHH) showed that negligible binding of IBU to the 457 
matrix molecules was found even after repeated exposure with 1000 µM. In accordance with these 458 
findings, IBU detected in the corresponding supernatants was in the range  95-108%. 459 
 460 
3.2 Kinetic profile of IBU in PRH 461 
The analyses of cell culture media at t0 revealed that a mean of 8.7 ± 0.7 µM and 85.3 ± 10.3 µM were 462 
applied  vs. a nominal concentrations of 10 µM and 100 µM, respectively, with a CV of 8-12% (N = 20 463 
per concentration).  464 
At 10 µM (low concentration) a similar IBU kinetic profile was observed on d0 and d13 both for the cell 465 
lysate and the supernatant compartments (Figure 2, A and B), indicating that the repeated treatment 466 
did not result in any saturation, inhibition or induction phenomena. A rapid and progressive 467 
intracellular uptake of IBU was evident from 2 min to 1 h. After a steady state from 1 to 3 h the amount 468 
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of IBU in the cell lysates decreased up to 24 h (Figure 2, A). In parallel, a non-proportional decrease 469 
was observed over time in the supernatant, indicating a steady state from 1 to 3 h followed by a drop 470 
to 3 and 12% of applied IBU at 24 h of d0 and d13, respectively (Figure 2, B). The non-quantitative 471 
correspondence between the decrease in the supernatants and the increase in the cell lysates over 472 
time was confirmed by the calculation of the mass balance (Figure 2, C), that is the total amount of 473 
IBU recovered in all the different compartments at a given time point, compared to the initially added 474 
amount. It indicated a ”apparent” loss of IBU over time (striped bars in Figure 2, C), which could be 475 
attributed to biotransformation processes (slightly lower on d13). 476 
At 100 µM IBU (high concentration), the  kinetic profile was similar (Figure 2, D and E): the low to high 477 
concentration ratio (1/10) was maintained in the IBU amount measured in cell lysates,  increasing on 478 
both days from 2 min to 1 h.  A steady state (1 to 3 h) followed and then a decrease to a minimum of 479 
~6 and 13% at 24 h (d0 and d13, respectively) (Figure 2, D). 480 
Figure 2 E illustrates the continuous decrease of IBU in the supernatant showing a steady state from 1 481 
to 3 h and a drop at 24 h to ~18 (day 0) and 36% (day 13) of the initial amount. The relative 482 
distribution in the different compartments again showed an apparent ‘loss’ in mass balance (Figure 2, 483 
F). 484 
 485 
3.3 Kinetic profile of IBU in PHH 486 
When the kinetic profile of IBU was followed in PHH, the different human donors were firstly evaluated 487 
individually rather than as biological replicates, due to high intra-individual variability. Although the 488 
absolute values were different, representing the expected variability among individuals, analysed 489 
donors exhibited a comparable trend: on this basis, distinct donors were handled as biological 490 
replicates.  491 
This high variability (translated in high SD bars) was very likely attributed to differences in metabolism, 492 
although the hepatic pathology of the donors might also have contributed. In order to characterise the 493 
competence of PHH to metabolise IBU, some CYP specific activities were measured in PHH from 494 
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each donor (Table 4). Of particular interest was CYP2C9, which is the main CYP involved in IBU 495 
metabolism. PHH from Donor B1032 were expected to show a low level of oxidative IBU metabolism. 496 
Indeed, after 3 days of repeated exposure, a high degree of cytotoxicity was observed at both 497 
concentrations. As a result, the experiment with PHH from Donor B1032 was stopped because it did 498 
not meet the criteria set in the experimental design, i.e. high concentration corresponding to TC10, thus 499 
assuming a nearly constant number of cells throughout the experimental treatment. As a 500 
consequence, biokinetic data reported on d13 included only samples from PHH from the Donors 501 
S1045 and B1050. 502 
The mean IBU concentration at T0 was 97.8 ± 10.0 µM and 803.7 ± 78.6 µM vs the nominal 100 µM 503 
and 1000 µM, respectively, with a CV of  2-20%% with N = 20 (for each concentration). 504 
At 100 µM (low concentration) no differences in IBU kinetic profile were evident between d0 and d13. 505 
IBU uptake by PHH was very rapid, reaching maximum values (5% of the applied concentration) after 506 
2 min at d0 and after 30 min at d13 (Figure 3, A). Subsequently, a steady state up to 3 h was followed 507 
by a decrease to a minimum of ~ 1% at 24 h. IBU content in the PHH supernatant samples showed an 508 
almost continuous decrease over time with a less pronounced steady-state at early times. In no case 509 
the intracellular amount and the decrease in the supernatant were quantitatively correlated (Figure 3, 510 
B). The sum of the amount of IBU found in the cell lysates plus supernatants declined quite rapidly 511 
starting from the first time point on d0 (Figure 3, C); on d13 the decreasing rate was slower, but after 512 
24 h in both cases very low IBU values were attained (10.2 ± 4.8% on d0 and 8.6 ± 4.3% on d13). As 513 
evidenced by the relative IBU distribution in the different compartments (Figure 3, C), IBU content in 514 
the cell lysate never exceeded 5%, the amount measured at the steady state, supporting the 515 
occurrence of a very efficient metabolism of the parent compound by PHH. 516 
The kinetic profile in the cell lysate over 24 h for the PHH treated with 1000 µM (high concentration; 517 
Figure 3, D) showed a different pattern; the high/low intracellular concentration ratio was > 10 fold. 518 
After a very rapid uptake into the cells, at 2 min the amount of IBU remained at a constant level 519 
(around 1-3%) at d0; although very variable among donors, the trend was similar at d13. In contrast, 520 
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the supernatants revealed a slight decrease at earlier time points, (Figure 3, E), then IBU levels were 521 
almost constant up to 24 h. On d0 the relative distributions showed a decline in total recovered IBU 522 
from cells plus supernatant (Figure 3, F), but never below 50%. After repeated exposures, the 3 h time 523 
point corresponded to very low recovery and nearly no variability between samples and donors, 524 
contradicting results obtained both at previous time points as well as at 24 h, when results were 525 
consistent with the overall kinetic behaviour were obtained. The data at 3 h were interpreted as a 526 
technical problem, since at 24 h cell were perfectly viable and CYP2C9 activity was present (data not 527 
shown), therefore the low metabolic capacity at 24 h cannot be attributed to cytotoxicity. Under these 528 
conditions, the decrease in IBU mass balance was around 20-30% with most IBU recovered in the 529 
supernatant at 24 h, as shown by its relative distribution (squared bars in Figure 3, F). This suggested 530 
a saturation of IBU biotransformation at 1000 µM, which could be expected at such a high 531 
concentration. 532 
 533 
3.4 Kinetic profile of IBU in HepaRG cells 534 
The actual IBU mean concentration in the media at t0 was 7.8 ± 1.2 µM and 85.4 ± 4.2 µM versus the 535 
nominal 10 µM and 100 µM, with a CV between 5 and 16% with N = 20 (for each concentration). 536 
In HepaRG cells treated with 10 µM IBU, the uptake started at 30 min, reaching a plateau after 3-6 h 537 
(Figure 4, A). In the supernatant a continuous decrease in IBU content was measured both on d0 and 538 
d13, reaching a similar amount at 24 h (Figure 4, B). The relative distribution showed a continuous 539 
and constant decrease of IBU mass balance in the course of 24 h both on d0 and d13. Although the 540 
reduction rate was higher after repeated exposure (Figure 4, C), likely attributable to higher level of 541 
CYP2C9 on d13. 542 
After treatment of HepaRG cells with 100 µM IBU (high concentration), the measured kinetic profile 543 
was similar: in the cell compartment on d0 and d13 IBU content remained low, under 0.5 nmol/well 544 
(Figure 4, D). A gradual decrease in IBU content was observed in the supernatants on d0 higher on 545 
d13, but never quantitatively related to the increase in intracellular content (Figure 4, E). The total IBU 546 
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recovery showed a continuous decrease over time on both days (Figure 4, F), although significantly 547 
lower on d13. This suggests a possible increase in the CYP2C9-related biotransformation capacity of 548 
this cell model over time. The IBU amount in the supernatants was 10 fold higher than that measured 549 
at 10 µM IBU, respecting the high/low concentration ratio, whereas it was < 10 in cell lysates. 550 
 551 
3.5 Pharmacokinetic Modelling 552 
Figure 5 shows the measured and modelled amount of IBU in the medium and cell lysates of PRH 553 
cultures over the repeated treatment of 14 days. Since IBU was applied daily, the concentration was 554 
reset to nominal medium concentrations every 24 h. It was assumed that IBU content in cell lysate 555 
corresponds to intracellular concentrations; the assumption was nevertheless reasonable, since, 556 
based on its low lipophilicity (log KOW = 0.8 at pH 7.4), IBU is unlikely sequestered within membranes. 557 
The data were well matched by the model and fairly consistent across replicates. The various curves 558 
were very similar, showing that there was reasonable uncertainty in the model predictions (the 559 
estimate of residual uncertainty corresponded to a CV of 30%). 560 
A dynamic equilibrium was reached already after the first day. The ratios Qcell over Qmed were close to 561 
0.2, but the total cellular volume was about a 1000th of the medium volume, so the ratio of 562 
concentrations was about 200. As a result, cells had a 200 times higher IBU concentration than the 563 
medium. 564 
A similar model fitted for PHH data is shown in Figure 6. The PHH from Donor B1032 proved to be 565 
very sensitive to IBU toxicity at the applied concentration, thus only data from the first day were 566 
obtained. Here, significant inter-individual variability was noted, thus a population approach was used 567 
to analyse the data deriving from PHH. The fits were quite good, but uncertainty (reflected by the 568 
spreading of the simulated curves) was as expected higher compared to PRH, resulting from 569 
underlying measurement errors and modelling approximations (the estimate of residual CV being 570 
40%). In two PHH donors, the intracellular quantity of IBU was noticeably higher than predicted. In the 571 
data sets of PHH from Donors S1045 and B1050, a dynamic equilibrium was reached practically on 572 
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d1, as previously seen in the modelling of the PRH data. The IBU amounts in PHH of the 100 µM 573 
group were underestimated by the model. This could be due to systematic error in IBU recovery, non-574 
linearity in cellular uptake of efflux, lower metabolism at IBU low concentration, or some unknown 575 
mechanism. More data would be required to identify the actual cause of this observation. 576 
The data and model fit for HepaRG cells are given in Figure 7. The applied model layout was similar to 577 
that previously described for PRH and PHH. As for the PHH data, the three replicates were analysed 578 
in a population framework, but reflecting inter-experiment variability instead of inter-individual 579 
differences between donors. There was a rather large proportion of non-detectable levels in the low-580 
dose experiments with substantial uncertainty (residual uncertainty: CV = 45%). Furthermore, an 581 
underestimation of some data points at 10 µM concentration in cell lysates was observed as 582 
previously observed for the PHH. These results seem however, globally consistent with those of the 583 
other two culture systems. For both PHH and HepaRG cells, the ratios Qcell over Qmed were close to 584 
0.01, indicating that those cells had only a 10 times higher IBU concentration compared to the medium 585 
– that is much less than in PRH, likely due to more efficient metabolism. 586 
The posterior parameter distributions obtained after MCMC sampling for the "average" parameters are 587 
summarised in Table 5. They characterise the kinetic behaviour observed an average experiment for 588 
PRH or HepaRG cells, or of the cells of an average donor in PHH. Given the dose assayed in the 589 
various systems and the cell capabilities, we could estimate a maximum rate of metabolism only in 590 
PHH. The low-dose metabolic clearances, Vmax / Km, could be estimated in all systems with very good 591 
precision in PRH (5% CV) and less so in PHH and HepaRG (50% CV). The PRH have clearly lower 592 
clearance rates, which explained the much higher IBU concentrations observed in those cells. 593 
Clearance rates were similar for the different human cells, given the significant variability between 594 
donors and experiments. In HepaRG cells, metabolic clearance is known to increase with time, and 595 
we estimated (slope parameter α) that it was about 60% higher after 14 days compared to the start 596 
(Table 5). 597 
598 
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4 Discussion 599 
To overcome the imbalance between rising costs and declining approvals of new drugs, the 600 
pharmaceutical industry is under pressure to improve the effectiveness of the drug development 601 
process, and reduce the current high attrition rates. Toxicity testing is crucial, but represents a time- 602 
and resource-consuming step; in addition human ADRs to the liver are often difficult to predict with 603 
existing animal models. These considerations, besides the ethical considerations related to the use of 604 
laboratory animals, promote the development of more suitable in vitro methods. This paper addresses 605 
the importance of measuring in vitro biokinetics, generally not taken into account even in well-606 
established experimental in vitro models, in order to improve the predictability of in vitro data, and to 607 
be used as input in PBPK models (Coecke et al., 2013). We used three different hepatic cellular 608 
systems, with IBU as a model compound. 609 
IBU is a widely used as analgesic/antipyretic agent, available by prescription and over-the-counter; at 610 
therapeutic doses it is reported, although rarely, to induce ADRs to the liver (Bennett et al., 2009; 611 
Rodríguez-González et al., 2002; Laurent et al., 2000). Among them, sub-acute hepatic failure, 612 
hepatitis C cases and significant increase in transaminases (O’Connor et al., 2003). In humans, the 613 
first step in IBU metabolism is catalysed by CYP2C9 and to a lower extent by 2C8 (Chang et al., 614 
2008), to form 2-Hydroxy-IBU and Carboxy-IBU, as major detoxification metabolites (Hamman et al., 615 
1997). The rat CYP2c6 and 2c11, orthologs of human CYP2C9 (Vecera et al., 2011), are thought to 616 
be involved in these oxidative reactions (Hu et al., 2011; Kapil et al., 2004). IBU and its oxidative non-617 
toxic metabolites are conjugated with glucuronic acid by different UGTs in vitro in rat or human 618 
hepatocytes (Dong and Smith, 2009) and in vivo (Spraul et al., 1992) and then excreted, mainly in 619 
urine. 620 
As the first step we checked factors possibly affecting the bioavailability of IBU under the experimental 621 
conditions used, and showed that IBU was readily soluble and chemically stable, neither cross-622 
contamination among wells nor adsorption to plastic devices occurred. The use of FBS or albumin in 623 
the medium was reduced to a minimum, i.e. not affecting IBU recovery or total bioavailability. 624 
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Furthermore, no IBU was physically sequestered into the Geltrex™ used in PHH SW culture. By 625 
contrast, we found a time- and concentration-dependent amount of IBU in collagen I used in PRH 626 
cultures. This finding was relevant because physically sequestered IBU could be assumed as 627 
intracellular content, and erroneously interpreted as bioaccumulation. 628 
The study design was similar to that of the in vivo kinetic testing (OECD Test Guideline 417). The 629 
comparison of kinetic behaviour obtained between single and repeated treatments allowed the study 630 
of inhibition, saturation or induction of cellular influx/efflux, metabolism and bioaccumulation 631 
processes. 632 
The used 100 µM IBU corresponds to 20.6 µg/mL, which approximates the recently reported human 633 
peak plasma concentration (Cmax = 22.6 ± 5.6 µg/mL) measured upon oral intake of 400 mg IBU 634 
(Vilenchik et al., 2012) in the low range of therapeutic doses. Hence, the cross-model comparison of 635 
the three hepatic systems was conducted at 100 µM IBU. 636 
The obtained modelled results showed a coherent picture for IBU in vitro biokinetics across the three 637 
models: (i) IBU quickly entered cells; (ii) after multiple exposures a dynamic equilibrium was reached 638 
within one or two days; (iii) the decrease in the medium was not quantitatively related to the increase 639 
in the cell lysate fractions. All three models showed a significant capacity in metabolising IBU; 640 
therefore, cells removed (by biotransformation) the parent compound in 24 h, resulting in no 641 
bioaccumulation after daily treatment for 14 days This is in line with information from in vivo 642 
pharmacokinetic data in humans showing that 60% of a given dose was excreted within the first 24 h 643 
(Adams et al., 1969). Although the experimental data were available only on d0 and d13, modelling 644 
allowed the prediction of the daily kinetic behaviour along the treatment period. 645 
The uptake of IBU was likely due to passive transport through the cell membrane, being very rapid 646 
and not saturable: and assumed to be a "first order" kinetic process. Our assumption was supported 647 
by experiments conducted on Caco2 cells indicating a passive transport (data not shown) and by data 648 
showing that in rats IBU is an Oatp1a1 inhibitor (Zhang et al., 2013) and in human cells IBU inhibits 649 
OATP1B1 or OATP1B3, without being a substrate (Kindal et al., 2011). The modelling showed that 650 
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cellular uptake was much faster compared to its output; since, once entered, the drug was rapidly 651 
metabolised, the efflux back in the medium compartment, if any, was considered negligible. An initial 652 
slower intracellular uptake characterised HepaRG cells (paralleled by a slower decrease of IBU 653 
content in the medium fraction, Figure 8 B at d0). It could be attributed to the presence of 2% FBS in 654 
the medium binding IBU. However, considering protein binding as a fast process, despite the cell 655 
uptake rate was initially slower, the total amount of IBU entering the cells within 24h was the same 656 
(>90% IBU ”lost” in the mass balance estimate). The consequence could be a slight overestimation in 657 
the HepaRG clearance.  658 
After single exposure, the steady state was reached rapidly in PHH (2-30min) > PRH (1-3h) > 659 
HepaRG (3-6h). The higher intracellular concentration detected in PRH than in human derived cells 660 
(Figure 8 A, C) at the steady state could be due to the different metabolic clearance rates, which in the 661 
rat model are one order of magnitude lower compared to the human-derived cells (Table 5). The 662 
difference in metabolic clearance was shown also in vivo (Adams et al., 1969), with a more efficient 663 
IBU metabolism in humans compared to the rat. 664 
The HepaRG cells showed lower IBU concentrations in the cell lysates than PHH, particularly after 665 
repeated treatment. This could be due, at least partially, to the 60% increase over time of IBU 666 
metabolic clearance in HepaRG cells (Table 5) which was not a compound-specific effect. Indeed, 667 
higher levels of CYP2C9 activity at 14 days of culture have been reported (Anthérieu et al., 2010) as 668 
well as for other CYPs (Jossé et al., 2008). In addition, transcriptomics measurements indicated no 669 
significant increase in CYP2C9 mRNA indicative of induction by IBU treatment, although few genes 670 
involved in drug metabolism were increased in control cells on d13 (data not shown). The absence of 671 
induction throughout the course of repeated exposure in the three models was in accordance with in 672 
vivo data (Mills et al., 1973). 673 
The efficiency of IBU metabolism seemed to be a strong determinant for its toxicity in hepatocytes. 674 
Here, PRH, with a slower metabolic clearance, showed a higher toxicity compared to PHH although, 675 
due to the high inter-individual variability in PHH, the obtained TC10 cannot be considered as 676 
 28 
 
representative of the average human population. Indeed, PHH from Donor B1032, characterised by 677 
low CYP2C9 activity and thus, by a low IBU detoxification, experienced a high cytotoxicity, leading to 678 
experiment termination after 3 days. It is unclear why TC10 in HepaRG was lower than PHH and 679 
similar to PRH, although having a much higher metabolic clearance. A possible explanation, beside 680 
the lower number of cells (50% of the population is made of biliary cells) is a different balance 681 
between phase-1 and phase-2 metabolism in the three models. Although not measured and modelled 682 
in this work, glucuronidation has been also shown to play a role in the metabolic disposition of most 683 
‘profens’ Since species differences have been described in glucuronidation rates in liver microsomes 684 
(rate ranking: man, monkey, dog, rabbit and rat) (Magdalou et al., 1990), phase 2 metabolism may 685 
contribute to differences in the total biotransformation as well as to IBU-induced toxicity among 686 
species and between the human-derived models. Indeed, ‘profen’-acyl glucuronides have been shown 687 
to form covalent protein adducts in rat hepatocytes (Dong and Smith, 2009), contributing to hepatic 688 
toxicity. Although IBU is glucuronidated less efficiently than other compounds of the same family 689 
(Magdalou et al., 1990) and IBU-acyl glucuronides are considered less reactive among those formed 690 
with other ‘profens’ (Castillo et al., 1995), their higher formation in the PHH from Donor B1032, due to 691 
the scant CYP2C9 activity, may be responsible for the pronounced toxicity.  692 
Here, the disappearance of the parent compound over time was used as a measure for metabolic 693 
clearance. The detection of the different metabolites, including glucuronides, would have delivered 694 
valuable additional information whether DMEs are differentially active in the three in vitro systems, 695 
accounting for the observed differences. The use of DME-phenotyped PHH could further help in the 696 
full understanding of metabolism-related IBU toxicity. Overall, the observed metabolism-dependent 697 
toxicity could be a hint to the rather idiosyncratic nature of IBU-induced liver injury in patients (Bennett 698 
et al., 2009; Rodríguez-González et al., 2002; Laurent et al., 2000). 699 
The importance of the intracellular concentration for concentration-response extrapolations was 700 
comprehensively described by Groothuis et al. (2013). Here we provide evidence that the use of 701 
nominal concentrations would have resulted in an overestimation of the actual treatment (up to 20%). 702 
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More importantly, the content in the cell lysates over time appeared to be different in the three hepatic 703 
models tested. The disappearance of the test item in the culture medium which was, from a technical 704 
point of view, less demanding than testing the cell lysate fraction, showed no major differences in the 705 
three hepatocyte models after repeated treatment. Hence, monitoring the biokinetic profile in this 706 
single compartment did not allow the drawing of any clear conclusions. Consequently, the 707 
measurement of the compound in the cell lysates and the calculation of the relative distributions using 708 
mass balance values, were crucial parameters to be monitored. 709 
Overall, in terms of species-differences, our data reflected the in vivo situation. Here, consideration of 710 
dose-normalised pharmacokinetic parameters such as Cmax (rat < human), Tmax (rat < human) and t1/2 711 
(rat ~ human) revealed that at 100 µM IBU was metabolised as in vivo more efficiently in humans 712 
compared to rats (Hu et al.,2011; Kapil et al., 2004; Teng et al., 2003; Adeyeye et al., 1996). Although 713 
PRH appeared to give reproducible results, as expected by the species-specificity, IBU intracellular 714 
concentration in PRH did not correspond to IBU intracellular concentrations found in human cells 715 
under similar exposure conditions, suggesting a poor predictivity from this species. A high variability 716 
was shown by PHH from the different donors, although modelling made it possible to account for (and 717 
in reduce) variability between donors. The residual uncertainty (Table 5 and in model prediction 718 
Figures) was overall about 10%. The number of donors tested was limited, but the use of an 719 
appropriately higher number of donors could provide an estimate of human variability, which may be 720 
considered an advantage, representing the inter-individual differences observed clinically. HepaRG 721 
cells gave very reproducible data and although a large population (~50%) of non-metabolising biliary 722 
cells is present, they did not bioaccumulate IBU. This was in line with previous data showing that 723 
cryopreserved HepaRG cells are a valuable tool for kinetic prediction of CYP substrates (Zanelli et al., 724 
2012). 725 
 726 
5 Conclusion 727 
 30 
 
The consideration of the biokinetic profiles could help explaining specific observations, i.e. 728 
transcriptome, proteome and enzyme induction/inhibition, and support a more holistic biological 729 
interpretation. Biokinetics is the link between the applied dose and the observed effects. Modelling 730 
these effects taking into account the time course of concentrations is at the root of time-based 731 
simulations of effects, i.e. pharmacokinetic/pharmacodynamic (PKPD) modelling, allowing one to 732 
make predictions from in vitro to in vivo effects. Finally, the transformation of an in vitro NOAEC to a 733 
relevant in vivo NOAEL would greatly benefit drug discovery and reduce the chance of hepatotoxic 734 
compounds making it through to clinical trials or on to the market. 735 
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Figure Legends 895 
Figure 1. Schematic representation of the three-compartment model used for ibuprofen in vitro 896 
pharmacokinetics. 897 
 898 
Figure 2. Kinetic profile of ibuprofen (IBU) (nmol/well) in primary rat hepatocytes (PRH) (A, D) and 899 
culture supernatants (B, E) after single (day 0 (d0) – dashed line) and repeated (day 13 (d13) – solid 900 
line) treatment with 10 µM IBU (A, B) or 100 µM IBU (D, E). Relative distribution (%) of IBU in the 901 
different analysed PRH fractions at the indicated time points for d0 and d13, supernatant (squared) 902 
and cell lysate (blank) as well as the apparent loss (striped) for the low concentration (10 µM, C) and 903 
high concentration (100 µM, F). Values are given as mean of three biological replicates +/- SD 904 
(standard deviation); each sample was run in two technical replicates. The significance of the results 905 
was analysed by the Student t test (p<0.05): the letter a indicates statistically significant differences 906 
between each data point and the first time point; the letter b indicates statistically significant 907 
differences between each data point and the immediately precedent time point. 908 
 909 
Figure 3. Kinetic profile of ibuprofen (IBU) (nmol/well) in primary human hepatocytes (PHH) (A, D) and 910 
culture supernatants (B, E) after single (day 0 (d0) – dashed line) and repeated (day 13 (d13) – solid 911 
line) treatment with 100 µM IBU (A, B) or 1000 µM IBU (D, E). Relative distribution (%) of IBU in the 912 
different analysed PHH fractions at the indicated time points for d0 and d13, supernatant (squared) 913 
and cell lysate (blank) as well as the apparent loss (striped) for the low concentration (100 µM, C) and 914 
high concentration (1000 µM, F). As the PHH from Donor B1032 evidenced a high cytotoxicity after 3 915 
days of treatment with IBU, values are given as mean of two (d13) or three (d0) biological replicates 916 
+/- SD; each sample was run in two technical replicates. 917 
 918 
Figure 4. Kinetic profile of ibuprofen (IBU) (nmol/well) in HepaRG cells (A, D) and culture supernatants 919 
(B, E) after single (day 0 (d0) – dashed line) and repeated (day 13 (d13) – solid line) treatment with 920 
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10µM IBU (A, B) or 100µM IBU (D, E). Relative distribution (%) of IBU in the different analysed 921 
HepaRG cell fractions at the indicated time points for d0 and d13, supernatant (squared) and cell 922 
lysate (blank) as well as the apparent loss (striped) for the low concentration (10 µM, C) and high 923 
concentration (100 µM, F). Values are given as mean of three biological replicates +/- SD; each 924 
sample was run in two technical replicates. The significance of results was analysed by the Student t 925 
test (p<0.05): the letter a indicates statistically significant differences between each data point and the 926 
first time point; the letter b indicates statistically significant differences between each data point and 927 
the immediately precedent time point. 928 
 929 
Figure 5. Amount of ibuprofen (IBU) in nmol, measured in the medium (triangles) and cell lysates 930 
(circles) of primary rat hepatocytes (PRH) cultures, superimposed with the best (maximum posterior) 931 
fit of the three-compartment pharmacokinetic model (thick black line) and a set of predictions 932 
generated from random set of posterior parameter values (thin black lines). IBU was applied daily at 933 
either high (100 µM corresponding to 150-200 nmol per day; top row A) or low concentration (10 µM 934 
corresponding to 15-20 nmol per day; bottom row B). Three biological replicates were analysed (in 935 
column, 1-3). 936 
 937 
Figure 6. Amount of ibuprofen (IBU) in nmol measured in the medium (triangles) and cell lysates 938 
(circles) of primary human hepatocytes (PHH) cultures, superimposed with the best (maximum 939 
posterior) fit of the three-compartment pharmacokinetic model (thick black line) and a set of 940 
predictions generated from random set of posterior parameter values (thin black lines). IBU was 941 
applied daily at either high (1000 µM corresponding to 1.5-2 µmol per day; top row A) or low 942 
concentration (100 µM corresponding to 150-200 nmol per day; bottom row B). Three donors were 943 
analysed (in column, 1-3) in population pharmacokinetic framework. Experiment with PHH from Donor 944 
B1032 was stopped, due to the toxicity of IBU to those cells. 945 
 946 
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Figure 7. Amount of ibuprofen (IBU) in nmol measured in the medium (triangles) and cell lysates 947 
(circles) of HepaRG cultures, superimposed with the best (maximum posterior) fit of the three-948 
compartment pharmacokinetic model (thick black line) and a set of predictions generated from random 949 
set of posterior parameter values (thin black lines). IBU was applied daily at either high (150-200nmol 950 
per day; top row A) or low concentration (10-20nmol per day; bottom row B). Three replicate 951 
experiments were analysed (in column, 1-3) in population pharmacokinetic framework. 952 
 953 
Figure 8. Cross model comparison between primary rat hepatocytes (PRH) (dashed line), primary 954 
human hepatocytes (PHH) (squares, solid line) and HepaRG cells (triangles, solid line): Biokinetic 955 
profile of ibuprofen (IBU) (nmol/well) in cell lysates (A, C) and culture supernatants (B, D) after single 956 
(day 0 (d0) – upper panel: A, B) and repeated (day 13 (d13) – lower panel: C, D) treatment with 100 957 
µM IBU. The five time point correspond to 2 min, 30 min, 1 h, 3 h and 24 h for PRH and PHH, and 30 958 
min, 3 h, 6 h, 12 h and 24 h for HepaRG cells. Values are given as mean of three biological replicates 959 
+/ SD; each sample was run in two technical replicates. 960 
961 
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Tables 962 
Table 1. Detailed information on the donors of liver resections utilised within this study.  963 
Donor Sex Age Pathology Medication 
S0302V
a
 Male 61 Sigmoid 
adenocarcinoma 
Lypanthyl, Stagid, 
Cotareg, Insulin, Sotalex 
B1032 Male 42 Echinococcosis 
alveolaris 
none 
S1045 Male 75 Hepatic tumor Atenolol, Kardegic, 
Ramipril, Inspra, Rasilez 
B1050 Male 63 Hydatid Cyst none 
 964 
a This sample was used only for a preliminary assessment of IBU cytotoxicity. It was not further used 965 
for the kinetic experiments,  966 
967 
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Table 2. Ibuprofen (IBU) concentrations applied to primary rat hepatocytes (PRH) cultures in different 968 
conditions for determination of the concentration that causes 10% cytotoxicity. 969 
Culture condition [IBU] in µM 
96-well (ML – 24h) 500 1000 1500 2000 3500 5000 
24-well (SW – 1, 3, 14d) 1 10 100 500 1000 2000 
  6-well (SW – 14d) 10 500 1000    
 970 
971 
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Table 3. IBU sequestered by collagen I used for primary rat hepatocytes (PRH) long-term cultures. 972 
  IBU in % 
d0 
2 min 1.6 ± 1.3 
(101.3 ± 1.3) 
3.4 ± 0.4 
(98.2 ± 0.3) 
24 h 13.6 ± 2.7 
(97.6 ± 5.8) 
15.1 ± 0.9 
(103.4 ± 2.2) 
d13 
2 min 29.3 ± 0.6 
(94.3 ± 3.1) 
28.5 ± 1.3 
(99.8 ± 5.6) 
24 h 31.4 ± 3.0 
(104.3 ± 0.9) 
26.4 ± 1.7 
(106.3 ± 1.7) 
 Nominal 
concentration 
IBU 10µM IBU 100µM 
 973 
Values are given in per cent of IBU detected in collagen I, compared with IBU detected in cell media at 974 
T0. Figures in parentheses are the total IBU recovery (media + collagen I). Results are expressed as 975 
mean ±standard deviation (SD) obtained on three replicates. 976 
d0 = day 0; d13 = day 13 977 
978 
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Table 4. Cytochrome P450 activities of primary human hepatocytes (PHH) from the three donors used 979 
for the biokinetic studies. 980 
 Activity in pmol/min/mg protein 
Donor CYP1A1/2 CYP2B6 CYP3A4 CYP2C9 CYP2D6 
B1032 < LOQ 5.33 0.104 3.81 0.281 
S1045 0.221 23.1 33.4 29.9 3.36 
B1050 0.140 22.1 < LOQ 15.1 0.809 
 981 
The specific activity of cytochrome P450s (CYP) in the hepatocyte preparations deriving from the 982 
three different donors was assessed one day after seeding. Results were expressed as average of 983 
two technical replicates.  984 
985 
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Table 5. Summary statistics of the posterior “population” mean parameters distribution of the in vitro 986 
ibuprofen (IBU) kinetic models in the three cellular systems. 987 
 988 
Parameter PRH values
a
 PHH values HepaRG cell values 
Fin 230 ± 25 [180, 290] 259 ± 75 [130, 440] - 
d 
Fout 24 ± 2.9 [17, 30] 45.8 ± 15 [23, 84] - 
d 
k1 
3.5×10-4 ± 7.4×10-5 
[2×10-4, 5.2×10-5] 
- d - d 
k2 
1.4×10-3 ± 3.3×10-4 
[7.4×10-4, 2.2×10-3] 
- d - d 
Vmax - 
b 
5.7×10-9 ± 3×10-9 
[2.2×10-9, 1.4×10-8] 
- b 
Vmax / Km 0.47 ± 0.02 [0.42, 0.5] 6.5 ± 3.0 [3.0, 15] 13 ± 6.5 [5.4, 30] 
 - 
c - c 
5.1×10-7 ± 1.4×10-7 
[2.5×10-7, 8×10-7] 
 989 
These posterior distributions were obtained by model calibration with the data. For PRH they 990 
characterise to a typical experiment; while for PHH they correspond to the geometric mean of a virtual 991 
population of hypothetical donors. For HepaRG cells they represent the geometric mean of a virtual 992 
set of experiments. 993 
a (mean ± SD) [2.5 and 97.5 percentiles of the posterior distribution]. 994 
b not applicable (first order kinetics). 995 
c not applicable (slope set to zero). 996 
d not applicable (fixed value parameter). 997 
998 
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Supplementary Data 999 
Table S1. Population mean parameters descriptions, set values or statistical distributions of the in vitro 1000 
IBU kinetic model for PHH. The posterior distributions were obtained by model calibration with the 1001 
data and represent the geometric mean of a virtual population of hypothetical donors. 1002 
Parameter Description Units Value or Prior distribution 
Ncell number of hepatocytes - 2 ×10
6 
Vmed volume of assay medium μm
3 2 ×1012 
Vcell volume of a cell μm
3 3400 c 
Fin cell entry rate flow 
a μm3.sec-1 U (0, 500) d 
Fout cell exit rate flow 
a μm3.sec-1 U (0, 106) 
k1 GelTrex™ binding rate constant sec
-1 0 
k2 GelTrex™ unbinding rate constant sec
-1 0 
Vmax maximum rate of metabolism 
a nmol.sec-1 U (0, 10-7) 
Vmax / Km low-dose metabolic clearance 
a,b μm3.sec-1 U (0, 106) 
a Per hepatocyte. 1003 
b At each iteration, Vmax was divided by this parameter to compute the Km value to use in Eq. 5. 1004 
c Lodish et al., 2000. 1005 
d U (min, max): uniform distribution. 1006 
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Table S2. Population mean parameters descriptions, set values or statistical distributions of the in vitro 1008 
IBU kinetic model for HepaRG cells. The posterior distributions were obtained by model calibration 1009 
with the data and represent the geometric mean of a virtual set of experiments. 1010 
Parameter Description Units Value or Prior distribution 
Ncell number of hepatocytes - 10
6 
Vmed volume of assay medium μm
3 2 × 1012 
Vcell volume of a cell μm
3 3400 b 
Fin cell entry rate flow 
a μm3.sec-1 150 
Fout cell exit rate flow 
a μm3.sec-1 30 
k1 protein binding rate constant sec
-1 0 
k2 protein unbinding rate constant sec
-1 0 
Vmax(t0) / Km initial metabolic clearance 
a μm3.sec-1 U (0, 106) c 
 clearance slope factor sec-1 U (0, 10-6) 
Nbcell number of biliary cells - 10
6 
a Per cell. 1011 
b Lodish et al., 2000. 1012 
c U (min, max): uniform distribution. 1013 
